Comparison of Top Two Shares of the Day: Horizon Pharma plc (NASDAQ:HZNP), Abbott Laboratories (NYSE:ABT)

u.s stocks , earnings estimates

Horizon Pharma plc (NASDAQ:HZNP)

Horizon Pharma plc (NASDAQ:HZNP) closed at $22.09 on the last trading session with an decrease of -1.56%, whereas, it previously closed at $22.44. The company has a market capitalization of $3.7 Billion. The company traded shares of 4.68 Million on the trading day while its three month average volume stands at 1.48 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Horizon Pharma plc (NASDAQ:HZNP) produced diluted EPS of -2.29. The EPS estimate for next year as estimated by analysts is at 1.86 while EPS for next quarter is estimated at 0.5. Earnings per Share growth for this year is reported at -186.7, while the analysts estimated the EPS growth for next year at 1.86% and Earnings growth for next 5 years stands at 18.9% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at -5.7%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Horizon Pharma plc (NASDAQ:HZNP) is at 0 while the forward p/e is at 11.9. The P/S or Price to Sales ratio of Horizon Pharma plc (NASDAQ:HZNP) stands at 3.45 and Price to Book or P/B for the most recent quarter stands at 4.25. The Price to Free Cash Flow ratio or P/FCF is reported at 17.73. The quick ratio and the current ratio of Horizon Pharma plc (NASDAQ:HZNP) are reported at 1.6 and 1.7 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Horizon Pharma plc (NASDAQ:HZNP) stands at -7.3, -32.4 and -12.6 respectively

The trailing twelve month Revenue of Horizon Pharma plc (NASDAQ:HZNP) is reported at 1.07 Billion with income of -375600000. The outstanding shares of Horizon Pharma plc (NASDAQ:HZNP) are 167.49 Million. The institutional Ownership of the shares of 92 stands at 0.80%, this figure is decreased -0.13 in the last six months. The insider ownership for the shares of Horizon Pharma plc (NASDAQ:HZNP) is ticked at 0.6%, the figure is plummeted -11.19% in the last six months.

Some other important financial aspects to be discussed here for Horizon Pharma plc (NASDAQ:HZNP) is the Mean Target Price estimated by the analysts which stands at 24.36. The 52 week high of Horizon Pharma plc (NASDAQ:HZNP) is placed at 22.76 and 52 week low is standing at 12.55.

Performance wise the shares of Horizon Pharma plc (NASDAQ:HZNP) rose up 13.87% for the week, it also rise 21.78% for the monthly performance, while for the quarter it went down 5.44%. The shares increase 55.02% for the half year and flew up for the Year-To-Date performance. The shares of Horizon Pharma plc (NASDAQ:HZNP) grew 64.85% for the yearly performance.

Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) closed at $72.96 on the last trading session with an increase of 0.63%, whereas, it previously closed at $72.5. The company has a market capitalization of $127.92 Billion. The company traded shares of 4.68 Million on the trading day while its three month average volume stands at 6.12 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Abbott Laboratories (NYSE:ABT) produced diluted EPS of 1.32. The EPS estimate for next year as estimated by analysts is at 3.2 while EPS for next quarter is estimated at 0.81. Earnings per Share growth for this year is reported at 44.6, while the analysts estimated the EPS growth for next year at 3.2% and Earnings growth for next 5 years stands at 11.47% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 47.4%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Abbott Laboratories (NYSE:ABT) is at 55.27 while the forward p/e is at 22.77. The P/S or Price to Sales ratio of Abbott Laboratories (NYSE:ABT) stands at 4.21 and Price to Book or P/B for the most recent quarter stands at 4.18. The Price to Free Cash Flow ratio or P/FCF is reported at 43.22. The quick ratio and the current ratio of Abbott Laboratories (NYSE:ABT) are reported at 1.1 and 1.4 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Abbott Laboratories (NYSE:ABT) stands at 1.2, 2.9 and 2.2 respectively

The trailing twelve month Revenue of Abbott Laboratories (NYSE:ABT) is reported at 30.4 Billion with income of 2.33 Billion. The outstanding shares of Abbott Laboratories (NYSE:ABT) are 1.75 Billion. The institutional Ownership of the shares of 74.9 stands at 0.80%, this figure is increased 0.16 in the last six months. The insider ownership for the shares of Abbott Laboratories (NYSE:ABT) is ticked at 0.3%, the figure is plummeted -6.8% in the last six months.

Some other important financial aspects to be discussed here for Abbott Laboratories (NYSE:ABT) is the Mean Target Price estimated by the analysts which stands at 78.94. The 52 week high of Abbott Laboratories (NYSE:ABT) is placed at 74.15 and 52 week low is standing at 54.32.

Performance wise the shares of Abbott Laboratories (NYSE:ABT) rose up 4.01% for the week, it also rise 5.86% for the monthly performance, while for the quarter it went down 13.95%. The shares increase 19.1% for the half year and flew up for the Year-To-Date performance. The shares of Abbott Laboratories (NYSE:ABT) grew 32.05% for the yearly performance.